OscarCommercial Clinical Policy

Difluprednate (Durezol) Ophthalmic Drops (PG079) Form

Chat with GenHealth to automate any policy or prior auth task.


Difluprednate (Durezol) Ophthalmic Drops for Initial Authorization

Notes: If all initial authorization criteria are met, Durezol will be approved for 6 months.

Indications

(341587) Is the difluprednate ophthalmic drop being used for the treatment of endogenous anterior uveitis? 
(341588) Is the difluprednate ophthalmic drop being used for inflammation and pain following ocular surgery? 
(341589) Has the patient been unable to use or tried and failed dexamethasone sodium phosphate 0.1% ophthalmic solution? 
(341590) Has the patient been unable to use or tried and failed FML Forte Liquifilm 0.25% ophthalmic suspension? 
(341591) Has the patient been unable to use or tried and failed prednisolone acetate 1% ophthalmic suspension? 

YesNoN/A
YesNoN/A
YesNoN/A

Sign up to see the rest of the questions

Unlock the remaining questions and the full coverage workflow.

Sign up for free
Effective Date

11/05/2020

Last Reviewed

09/21/2022

Original Document

  Reference



Durezol (difluprednate)

Durezol (difluprednate) is an ophthalmic steroid eye drop used to treat endogenous anterior uveitis or for inflammation and pain associated with eye surgery. Uveitis is inflammation inside the eye and can be treated with topical steroids. Surgery on the eye can cause pain and inflammation, which can be treated with steroid or non-steroidal anti-inflammatory drug (NSAID) eye drops.

Definitions

\

Book a walkthrough

Walk through this policy with us

Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.